Onconova Therapeutics Story

Onconova Therapeutics Inc -- USA Stock  

USD 1.03  0.03  3.00%

Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance
Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security

Onconova Therapeutics Inc insider trading alert for conversion of series c convertible preferred stock by Michael Hoffman, the corporate stakeholder, on March 8, 2018. This event was filed by Onconova Therapeutics Inc with SEC on 2013-08-01. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 3.77% .

Similar stores for Onconova Therapeutics

Stock-research Ratings Onconova Therapeutics, Inc. , Overseas Shipholding Group, Inc.news
Analyst JournalFull coverage
few days ago at http://postanalyst.com 
What The Crystal Ball Gazers Advise Onconova Therapeutics, Inc. ONTX ...
Post Analyst - Mar 16, 2018 Onconova Therapeutics, Inc. is maintained at an average outperform rating by 4 stock analysts, and there are at least 5.01 percent of shares outstanding that are currently legally short sold. Brokerages Set Onconova Therapeutics Inc Target Price at 8.00 - The Lincolnian Online
over a week ago at http://postanalyst.com 
A Preview of Valuations Summary Sanofi , Onconova Therapeutics, Inc.
Sanofi current PS is an impressive 2.27. The overall Drug Manufacturers - Major group has an average PS ratio of 6.15, which is significantly better than the sector 8.74.
over a week ago at http://postanalyst.com 
Institutionals Holders Overview For Onconova Therapeutics, Inc.
Post AnalystOnconova Therapeutics CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript Seeking AlphaFull coverage

Did you try this?

Run Financial Widgets Now

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Hide  View All  NextLaunch Financial Widgets

Return On Asset

Return On Asset Comparative Analysis
  Return On Asset 
      Onconova Therapeutics Comparables 
Onconova Therapeutics is currently under evaluation in return on asset category among related companies. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.